Pulmonary space-occupying lesion
Conditions
Interventions
Esketamine group:Intravenous injection of Esketamine in multiple small doses
Control group:Inject the same dose of normal saline before induction and operation.
Sponsors
People's Hospital of Deyang
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ? Age: 18-65 years old, 18.5 < BMI < 28; ? ASA grade I, II, and III patients who undergo selective thoracoscopic partial pneumonectomy (including lobectomy, segmental pneumonectomy, wedge resection); ? Be able to understand the research process, operate PCIA equipment, and effectively communicate with researchers; ? Voluntarily participate and sign the informed consent form. ? The operation time is within three hours.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic to the active ingredient of Esketamine or any ingredient of this product; 2. Patients with serious risk of elevated blood pressure or intracranial pressure; 3. Hypertension patients with poor control or without treatment (arterial hypertension, resting systolic/diastolic blood pressure exceeding 180/100mmHg); 4. Patients with hyperthyroidism without treatment or insufficient treatment; 5. Those who need other operations at the same time of the operation, or have complications that affect the evaluation of the study during and after the operation; 6. Those who are informed and unwilling to participate in the study; 7. Patients admitted to ICU after operation; 8. Patients who have or have had a history of serious mental disorders; 9. Patients with congestive heart failure, severe angina pectoris in the past, unstable angina pectoris or myocardial infarction in the past six months; 10. Before being included in the study, each patient was tested on the ability of visual analog score (VAS), patient-controlled analgesia (PCA) pump operation, answering the phone and understanding the Neuropathic Pain Syndrome Scale (NPSI). Patients who did not meet these criteria were excluded from the study; 11. Pregnant and lactating women; 12. Those who have participated in other clinical trials in the past three months;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of nausea and vomiting;Amount of sufentanil used; | — |
Countries
China
Contacts
Public ContactZhang Xianjie
People's Hospital of Deyang City
Outcome results
None listed